BrainsWay Deep TMS

10/06/2026

Leading practices will be there on November 4. Will you?

The practices growing fastest in interventional psychiatry aren't guessing. They're learning from the people who are already doing it.
On Wednesday, Nov 4, 12+ of the field's top clinicians and practice leaders are going live for one afternoon to share what's working right now: the protocols, the playbooks and the real numbers behind real practices.

Here's what you'll miss if you're not in the room:
🔹 What's new at BrainsWay, before everyone else hears about it
🔹 The SWIFT Protocol, and what it means for your schedule
🔹 Deep TMS + Ketamine: how leading practices are combining them
🔹 Neuromodulation at Home, the next frontier
🔹 Real case studies from the people who ran them
🔹 Launch and Growth Labs: the practice-building playbook, live

One afternoon. 12+ industry leaders. Limited virtual seats.

👉 Claim your seat before it's gone: https://hubs.li/Q04zkgkk0
📅 Wed, Nov 4 · 11 AM–4 PM ET · Virtual

07/01/2026

We’re proud to be featured in USA Today, helping shine a light on a mental health treatment that millions of Americans still don’t know exists.

While medication is often the first line of treatment, many patients continue searching for another option. That’s where Deep TMS™ comes in.

Mental health care is evolving, and awareness is the first step toward helping more people access effective treatment.

Thank you to USA TODAY and Radial for helping bring greater visibility to the future of mental health care.

Owen Muir MD DFAACAP, FCTMSS
Colleen Hanlon

Read the full feature below.



https://www.usatoday.com/story/sponsor-story/acumen-usa250/2026/07/01/the-life-changing-mental-health-treatment-most-americans-dont-know-exists/90681643007/

06/22/2026

Join some of the leading voices in interventional psychiatry and neuromodulation for a live conversation on the future of mental health care. This discussion will explore where psychiatry is headed, emerging treatment innovations, evolving patient needs, and how technologies like Deep TMS are shaping the next generation of care. Tune in for an engaging, unscripted exchange of ideas from experts helping define the future of psychiatry.

01/05/2026

🧠 Meet Simcha Cohen

Founder of BrainBody, Simcha is a local Psychiatric Nurse Practitioner using Deep TMS to help patients who are struggling when first-generation treatments fall short.

In this interview with WGN9 in Chicago, Simcha explains what Deep TMS is, how it works, and how their practice is using it to support patients living with Major Depressive Disorder, OCD, and other difficult-to-treat conditions.

Watch the full video interview to hear Simcha’s perspective and learn more about TMS:
https://wgntv.com/news/tms-transcranial-magnetic-stimulation-treatment-for-depression-anxiety/

At BrainsWay, we’re proud to support providers who are expanding access to evidence-based, non-invasive mental health treatment options.

Simcha Cohen is a local Psychiatric Nurse Practitioner and founder of BrainBody TMS … talking about transcranial magnetic stimulation and how they’re using it to help patients who are s…

12/24/2025

Wishing our community a season filled with warmth, reflection, and time with loved ones.

Thank you for being part of our journey this year. We look forward to what’s ahead together.

Happy Holidays from all of us at BrainsWay. ❄️

12/22/2025

Expanding access for adolescent mental health care.

We’re pleased to share that Optum Behavioral Health has expanded its medical policy to include coverage for Deep TMS™ therapy for adolescents aged 15 and older with confirmed major depressive disorder (MDD) — now adding over 48 million covered lives to the growing list of payers supporting this important option.

Deep TMS is FDA-cleared as an adjunct therapy for adolescents with MDD, building on its established role in adult care and supported by robust clinical evidence.

This coverage expansion reflects continued progress in broadening access to non-drug treatment options for young people facing depression.

https://ow.ly/WzaN50XNe2k

11/24/2025

The FDA has granted 510(k) clearance for TMS as an adjunctive treatment for Major Depressive Disorder in young people ages 15–21.

Real-world data from more than 1,100 patients across 35 centers showed strong safety and meaningful improvement in depression symptoms.

This clearance expands access to a much-needed, noninvasive treatment option for younger patients and supports continued innovation in neuromodulation.

👉 Read the full Healio article here:
https://www.healio.com/news/psychiatry/20251119/fda-grants-510k-clearance-for-tms-as-adjunctive-for-major-depressive-disorder-in-young-people

11/21/2025

Deep TMS™ becomes first and only TMS device cleared in treatment of patients ages 15 to 86 suffering from depression

Learm more: https://ow.ly/vJE250XvLx2

11/10/2025

We’re excited to be attending the Behavioral Health Tech Conference in San Diego, November 11–13!

Join us as we connect with leaders advancing mental health innovation and explore how Deep TMS® technology is shaping the future of behavioral health care.

If you would like to arrange a meeting with the BrainsWay team, please email [email protected].